망막 영상 진단 기기 시장 : 장비 유형, 접속성, 휴대성, 적응증, 유통 채널, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Retinal Imaging Devices Market is projected to grow by USD 7.70 billion at a CAGR of 8.07% by 2032.

Retinal Imaging Devices Executive Summary

Retinal imaging devices are becoming core infrastructure for ophthalmology, optometry, diabetes care, neurology research, and population health screening. Fundus cameras, optical coherence tomography (OCT), scanning laser ophthalmoscopes, fluorescein angiography systems, ultra-widefield systems, and portable retinal cameras help clinicians document the retina, optic nerve, macula, and retinal vasculature with high diagnostic value.

Demand is supported by verified public-health drivers: the World Health Organization reports that at least 2.2 billion people have near or distance vision impairment, while diabetes remains a major cause of preventable vision loss through diabetic retinopathy. As health systems prioritize earlier detection, retinal imaging devices are shifting from specialist-only equipment to connected diagnostic platforms used across hospitals, eye clinics, primary care, pharmacies, and mobile screening programs.

Transformative Shifts in the Retinal Imaging Landscape

The retinal imaging landscape is being reshaped by non-mydriatic imaging, widefield visualization, swept-source OCT, handheld retinal cameras, cloud-based image management, and teleophthalmology. These advances reduce patient burden, improve image capture in decentralized settings, and support screening models that address ophthalmologist shortages.

Procurement decisions are increasingly based on workflow integration, interoperability with electronic health records, cybersecurity, image quality, and total cost of ownership. Device makers are also responding to demand for portable, AI-ready, and multimodal platforms that can support diabetic retinopathy, glaucoma, age-related macular degeneration, and retinal vascular disease assessment.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is producing a cumulative impact across retinal imaging by improving triage, image grading, quality control, and referral prioritization. FDA-authorized autonomous AI systems for diabetic retinopathy screening have validated clinical use cases in primary care, while peer-reviewed research continues to expand AI applications in glaucoma, age-related macular degeneration, cardiovascular risk signals, and neurodegenerative disease markers.

The strongest commercial value comes when AI is embedded into the full workflow: automated image capture guidance, immediate quality assessment, risk stratification, standardized reporting, and follow-up tracking. However, leaders must manage algorithm bias, local validation, explainability, privacy, cybersecurity, and regulatory compliance before scaling AI-enabled retinal imaging across diverse populations.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, Africa

North America benefits from advanced ophthalmic infrastructure, high diabetes screening needs, reimbursement pathways, and early adoption of AI-enabled diagnostics. The United States leads in regulatory activity and clinical deployment, while Canada supports teleophthalmology programs for remote, rural, and underserved communities.

Europe emphasizes evidence-based procurement, data protection, and interoperable digital health systems, with the European Union shaping compliance expectations through medical device and health data governance frameworks. Asia-Pacific is a major opportunity base due to large diabetes populations, aging demographics, and government-backed screening initiatives across China, India, Japan, South Korea, Australia, and ASEAN markets.

Latin America is advancing through private eye-care networks and diabetes programs in Brazil and Mexico, where retinal imaging supports earlier referral and chronic disease monitoring. The Middle East, particularly GCC countries, is investing in specialty hospitals, digital health platforms, and advanced diagnostic infrastructure. Africa remains underpenetrated but highly relevant for portable, lower-cost, and mobile retinal screening models that can extend access beyond tertiary eye-care centers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN demand is shaped by rising diabetes prevalence, urban eye-care expansion, and the need for portable retinal imaging in mixed public-private health systems. BRICS markets combine large patient pools with expanding healthcare infrastructure and domestic manufacturing priorities, making affordability, service networks, local training, and scalable screening critical to adoption.

The G7 remains influential in clinical validation, reimbursement evidence, regulatory approvals, and premium OCT adoption across ophthalmology and optometry settings. The European Union sets strong benchmarks for data governance, medical device regulation, clinical evidence expectations, and cross-border digital health interoperability.

GCC countries are accelerating adoption through hospital modernization, national health strategies, diabetes prevention programs, and specialist investments. NATO countries, while not a healthcare market bloc, largely overlap with high-income systems where procurement resilience, cybersecurity, trusted supply chains, and secure medical data exchange increasingly influence retinal imaging device selection.

Key Country Insights Across Major Retinal Imaging Markets

The United States drives innovation through advanced ophthalmology networks, FDA-cleared AI diagnostics, high OCT utilization, and established diabetic eye screening pathways. Canada prioritizes remote access, equitable screening, and teleophthalmology models for underserved populations. Mexico and Brazil show rising adoption through diabetes care expansion, private-sector diagnostic capacity, and growing use of retinal imaging in specialty eye-care services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support demand through aging populations, public health systems, ophthalmology referral pathways, and increasing use of OCT for macular disease and glaucoma management. Russia presents demand for hospital-based imaging amid procurement complexity and regional access variation. China and India represent major volume opportunities due to large diabetes and aging populations, with affordability, local distribution, training, and scalable screening infrastructure as decisive factors.

Japan and South Korea lead in high-quality imaging adoption, precision diagnostics, and technology integration across specialist eye-care settings. Australia combines strong optometry networks with telehealth use cases, especially for rural, remote, and Indigenous health access, where portable retinal imaging can improve screening coverage and referral coordination.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize AI-ready retinal imaging platforms, cloud connectivity, cybersecurity, and interoperability with ophthalmology systems and enterprise health records. Product strategies should include modular pricing, portable devices, and service packages that support hospitals, retail optometry, primary care, community clinics, and mobile screening programs.

Commercial teams should align with diabetes screening programs, aging-care initiatives, public health outreach, and teleophthalmology providers. Manufacturers can strengthen adoption by investing in local clinical validation, operator training, image-quality protocols, service uptime, and post-market evidence that demonstrates earlier detection, reduced referral burden, and improved care continuity.

Research Methodology

This executive summary is developed using a structured secondary-research methodology aligned with evidence-based industry analysis standards. Inputs include public health data from organizations such as the World Health Organization and International Diabetes Federation, medical device regulatory information, peer-reviewed ophthalmology literature, reimbursement and digital health policy review, and verified disclosures from retinal imaging and ophthalmic technology providers.

Insights are triangulated across disease burden, clinical workflow adoption, technology readiness, regional healthcare infrastructure, regulatory environment, and procurement behavior. Qualitative assessment is used where market practices differ by country, with emphasis on verified trends and data-backed insights rather than speculative market sizing, market share, or forecasting.

Conclusion

Retinal imaging devices are moving from diagnostic instruments to connected platforms that support preventive eye care, chronic disease management, and AI-assisted clinical decision-making. Demand is supported by durable health drivers, including diabetes, aging populations, glaucoma, macular disease, retinal vascular disorders, and the need for scalable screening.

The next phase of competition will favor solutions that combine high-quality imaging, validated AI, workflow integration, secure data management, and accessible deployment models. Organizations that solve both clinical accuracy and operational scalability will be best positioned in the global retinal imaging devices landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Retinal Imaging Devices Market, by Device Type

• 7.1. Fundus Cameras
  • 7.1.1. Mydriatic Fundus Cameras
  • 7.1.2. Non-Mydriatic Fundus Cameras
• 7.2. Optical Coherence Tomography Systems
• 7.3. Wide-Field Imaging Systems
• 7.4. Scanning Laser Ophthalmoscopes
• 7.5. Retinal Angiography Systems

8. Retinal Imaging Devices Market, by Connectivity

• 8.1. Standalone Systems
• 8.2. Networked Systems
• 8.3. Cloud-Connected Systems

9. Retinal Imaging Devices Market, by Portability

• 9.1. Tabletop Devices
• 9.2. Stand-Mounted Devices
• 9.3. Handheld Devices
• 9.4. Smartphone-Enabled Systems

10. Retinal Imaging Devices Market, by Indication

• 10.1. Diabetic Retinopathy
• 10.2. Retinal Vein Occlusion
• 10.3. Glaucoma
• 10.4. Age-Related Macular Degeneration (AMD)
• 10.5. Uveitis & Inflammatory Diseases

11. Retinal Imaging Devices Market, by Distribution Channel

• 11.1. Online Sales
• 11.2. Offline Sales

12. Retinal Imaging Devices Market, by Application

• 12.1. Disease Diagnosis & Management
• 12.2. Research & Outreach
• 12.3. Systemic Screening
• 12.4. Surgical & Pre-operative Planning

13. Retinal Imaging Devices Market, by End User

• 13.1. Ambulatory Surgical Centers
• 13.2. Hospitals & Clinics
• 13.3. Ophthalmology Clinics
• 13.4. Community Screening Programs
• 13.5. Academic & Research Institutes

14. Retinal Imaging Devices Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Retinal Imaging Devices Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Retinal Imaging Devices Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Alcon Inc.
• 18.2. Bausch Health Companies Inc.
• 18.3. Canon Inc.
• 18.4. Carl Zeiss AG
• 18.5. EarlySight SA
• 18.6. Epipole Ltd.
• 18.7. EssilorLuxottica SA
• 18.8. Eyenuk, Inc.
• 18.9. Forus Health Pvt. Ltd.
• 18.10. Haag-Streit Group
• 18.11. Halma plc
• 18.12. Heidelberg Engineering GmbH
• 18.13. iCare Finland Oy by Revenio Group Corporation
• 18.14. Ikerian AG
• 18.15. Konan Medical, Inc.
• 18.16. Kowa Company, Ltd.
• 18.17. Natus Sensory, Inc.
• 18.18. NeoLight, LLC
• 18.19. NIDEK Co., Ltd.
• 18.20. Nikon Corporation
• 18.21. Olympus Corporation
• 18.22. Optain Health
• 18.23. Optomed Plc
• 18.24. Remidio Inc.
• 18.25. Robert Bosch GmbH
• 18.26. Santec Corporation
• 18.27. Sony Electronics Inc.
• 18.28. Tomey Corporation
• 18.29. Topcon Corporation
• 18.30. TowardPi (Beijing) Medical Technology Ltd
• 18.31. Visionix Group